US 11,945,871 B2
Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
Alemseged Truneh, Sudbury, MA (US); Daniel Olive, Marseilles (FR); Christine Pasero, Marseilles (FR); and Aude De Gassart, Marseilles (FR)
Assigned to IMCHECK THERAPEUTICS SAS, Marseilles (FR); INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); UNIVERSITE AIX MARSEILLE, Marseilles (FR); INSTITUT JEAN PAOLI & IRENE CALMETTE, Marseilles (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, Paris (FR)
Filed by Imcheck Therapeutics SAS, Marseilles (FR); INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); Université d'Aix Marseille, Marseilles (FR); Institut Jean Paoli & Irene Calmette, Marseilles (FR); and Centre National de la Recherche Scientifique—CNRS, Paris (FR)
Filed on Jun. 1, 2023, as Appl. No. 18/327,127.
Application 18/327,127 is a continuation of application No. 17/935,154, filed on Sep. 26, 2022.
Application 17/935,154 is a continuation of application No. 17/264,507, previously published as PCT/EP2019/070693, filed on Jul. 31, 2019.
Claims priority of application No. 18306050 (EP), filed on Aug. 1, 2018; and application No. 19153992 (EP), filed on Jan. 28, 2019.
Prior Publication US 2023/0322932 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 9/19 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 9/19 (2013.01); A61K 38/2013 (2013.01); A61K 38/2086 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/56 (2013.01)] 14 Claims
 
1. An isolated anti-BTN3A antibody comprising a variable heavy chain polypeptide VH of SEQ ID NO:1 and a variable light chain polypeptide VL of SEQ ID NO:2.